Sentence examples for are ongoing phase from inspiring English sources

96 There are ongoing phase II studies looking at everolimus as a single agent and in combination with imatinib (Gleevec; Novartis) for STS.

22, 40 There are ongoing phase 2 trials for sirolimus, temsirolimus, everolimus, and ridaforolimus; also, a phase 3 trial for ridaforolimus as maintenance therapy in sarcoma has completed enrollment.

In addition to targeting CD279, there are ongoing phase 1 clinical trials investigating the role of CD279 ligands: CD274/programmed death ligand (PD-L -1 in PD-L -1s PD-L -1lin tumors [ClinicalTrials.gov:NCT00729664] and CD273/patients stage IV melanoma patients [ClinicalTrials.gov:NCT00658892].

While preclinical research is ongoing, phase I and II clinical trials with bevacizumab, combretastatin A-4, thalidomide and different receptor tyrosine kinase inhibitors, usually combined with radio- and chemotherapy, have been designed.

Of these, currently 110 trials of AD therapies are ongoing: 26 Phase 1 trials representing 22 unique therapies; 54 Phase 2 trials assessing 49 unique treatments; and 30 trials Phase 3 testing 23 therapeutic compounds.

Quite a few other clinical trials testing nicotinic agonists are ongoing (ladostigil hemitartrate, phase 2; ispronicline, phase 1), completed (RO5313534), or terminated (ABT-089).

Further investigations as to the role of this device are ongoing in a phase II study.

These trials are ongoing, as are phase II monotherapy studies of first- and second-line treatment in patients with NSCLC in which ZD0473 is being given at a dosage of 120 150 mg m−2 every 3 weeks.

A number of other studies investigating the benefit of Akt inhibitors in OC are ongoing, and a phase II trial (NCT01283035) of the oral allosteric inhibitor (MK2206) of AKT1, AKT2, and AKT3 has just completed the recruitment phase.

Phase I combination studies are ongoing, whereas single-agent phase II studies in NSCLC and renal carcinoma have been initiated.

Many of the inhibitors are ongoing in different phases of clinical trials, shown in Figure 2, and show promising therapeutic value, but also exhibit poor selectivity and specificity to PLK-1.